Cargando…

Successful dual antiviral therapy with remdesivir and ensitrelvir in a case of prolonged COVID-19 following B-cell depleting immunotherapy for malignant lymphoma

Prolonged COVID-19 following B-cell depleting immunotherapy for malignant lymphoma is characterized by repeated cycles of remission followed by symptom recurrence, persistent detection of SARS-CoV-2, and profound humoral immunodeficiency. To the best of our knowledge, the present report is the first...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Seowoong, Yagi, Yu, Fukushima, Kazuaki, Nishikawa, Yukari, Tanaka, Masaru, Kobayashi, Taiichiro, Yajima, Keishiro, Ajisawa, Atsushi, Imamura, Akifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482734/ https://www.ncbi.nlm.nih.gov/pubmed/37693339 http://dx.doi.org/10.1016/j.idcr.2023.e01890

Ejemplares similares

Changes in rapid plasma reagin titers in patients with syphilis before and after treatment: A retrospective cohort study in an HIV/AIDS referral hospital in Tokyo
por: Ikeuchi, Kazuhiko, et al.
Publicado: (2023)

An analysis of the radiological factors associated with respiratory failure in COVID-19 pneumonia and the CT features among different age categories
por: Fukuda, Akito, et al.
Publicado: (2021)

Correction to: An analysis of the radiological factors associated with respiratory failure in COVID-19 pneumonia and the CT features among different age categories
por: Fukuda, Akito, et al.
Publicado: (2021)

Prevalence of thromboembolic events and status of prophylactic anticoagulant therapy in hospitalized patients with COVID-19 in Japan
por: Fujiwara, Sho, et al.
Publicado: (2021)

Multiple Lung Cysts Due to pneumocystis jirovecii Pneumonia
por: Fukushima, Kazuaki, et al.
Publicado: (2017)

Development of a Manufacturing Process toward the Convergent Synthesis of the COVID-19 Antiviral Ensitrelvir
por: Kawajiri, Takahiro, et al.
Publicado: (2023)

Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2
por: Yang, Yujian, et al.
Publicado: (2023)

Erythema Migrans-like Rash Mimicking Lyme Disease
por: Fukushima, Kazuaki, et al.
Publicado: (2019)

Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: a single-center retrospective observational study in Tokyo, Japan
por: Nakamura, Shohei, et al.
Publicado: (2020)

In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir
por: Kiso, Maki, et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model
por: Fukao, Keita, et al.
Publicado: (2023)

Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo
por: Kuroda, Takayuki, et al.
Publicado: (2023)

548. Combined Results of the Phase 2a/2b/3 Randomized Controlled Trials of Ensitrelvir for the Treatment of COVID-19 Infection
por: Tsuge, Yuko, et al.
Publicado: (2023)

Safety profile of the antiviral drug remdesivir: An update
por: Fan, Qianqian, et al.
Publicado: (2020)

Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults
por: Shimizu, Ryosuke, et al.
Publicado: (2022)

Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants
por: Lin, Mengmeng, et al.
Publicado: (2023)

Severe Thrombocytopenia and Acute Cytomegalovirus Colitis during Primary Human Immunodeficiency Virus Infection
por: Furuhata, Masanori, et al.
Publicado: (2016)

Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally
por: Kawashima, Sho, et al.
Publicado: (2023)

Novel Investigational Anti-SARS-CoV-2 Agent Ensitrelvir “S-217622”: A Very Promising Potential Universal Broad-Spectrum Antiviral at the Therapeutic Frontline of Coronavirus Species
por: Eltayb, Wafa A., et al.
Publicado: (2023)

Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia
por: Petrakis, Vasilis, et al.
Publicado: (2022)

Past, Present, and Future of Remdesivir: An Overview of the Antiviral in Recent Times
por: Choudhury, Shouvik, et al.
Publicado: (2020)

Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance
por: Ip, Jonathan Daniel, et al.
Publicado: (2023)

549. Ensitrelvir for the Treatment of COVID-19 Infection: Evaluation of Taste Disorder and Smell Disorder in the Phase 3 Part of the Phase 2/3 SCORPIO-SR Randomized Controlled Trial
por: Tsuge, Yuko, et al.
Publicado: (2023)

Rethinking Remdesivir: Synthesis, Antiviral Activity and Pharmacokinetics of Oral Lipid Prodrugs
por: Schooley, Robert T., et al.
Publicado: (2021)

Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs
por: Schooley, Robert T., et al.
Publicado: (2021)

Remdesivir for pregnancy: A systematic review of antiviral therapy for COVID-19
por: Budi, David Setyo, et al.
Publicado: (2022)

Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease
por: Noske, Gabriela Dias, et al.
Publicado: (2023)

Coronavirus disease 2019-associated thrombotic microangiopathy treated with plasma exchange and antihypertensive therapy in a patient with HIV: A case report with literature review
por: Masuda, Eriko, et al.
Publicado: (2023)

A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations
por: Shimizu, Ryosuke, et al.
Publicado: (2023)

537. Safety and Effectiveness of Ensitrelvir for the Treatment of COVID-19 in Japanese Clinical Practice: A Post-marketing Surveillance (Interim Analysis)
por: Ogura, Eriko, et al.
Publicado: (2023)

Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects
por: Humeniuk, Rita, et al.
Publicado: (2020)

Remdesivir and its antiviral activity against COVID-19: A systematic review
por: Frediansyah, Andri, et al.
Publicado: (2021)

Remdesivir, la esperanza antiviral frente al SARS-CoV-2
por: Reina, Jordi
Publicado: (2020)

Sulfobutylether-beta-cyclodextrin-enabled antiviral remdesivir: Characterization of electrospun- and lyophilized formulations
por: Szente, Lajos, et al.
Publicado: (2021)

The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance
por: Yan, Daisy, et al.
Publicado: (2021)

Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection
por: Heyer, Andreas, et al.
Publicado: (2022)

Small change for big improvement in the preparation of the key intermediate N(1), N(3)-disubstituted 1,3,5-triazone of ensitrelvir
por: Hu, Wei, et al.
Publicado: (2023)

Evaluation of the Drug–Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults
por: Shimizu, Ryosuke, et al.
Publicado: (2023)

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
por: Agostini, Maria L., et al.
Publicado: (2018)

Off-Target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent
por: Xu, Yili, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ht9tll3davck2oc501aq6j96jm